Jin Z, et al. - Researchers examined 796 patients with esophageal or gastroesophageal junction adenocarcinoma to assess the prognostic influence of pathologically confirmed esophageal adenosquamous carcinoma (ASC) and its relation with HER2 status and clinicopathologic features. They observed more prevalence of esophageal ASC among females, candidates with normal body mass index, and those who have HER2-negative tumors, vs adenocarcinoma only. About 16% of adenocarcinoma (only) tumors were HER2-positive vs 0% of ASC tumors. They noticed much worse disease-specific survival and overall survival (independent of known prognostic factors and HER2 status) in candidates with ASC vs those with adenocarcinoma only.